Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. Tolaney SM, et al. Among authors: sahebjam s. Clin Cancer Res. 2020 Oct 15;26(20):5310-5319. doi: 10.1158/1078-0432.CCR-20-1764. Epub 2020 Jul 21. Clin Cancer Res. 2020. PMID: 32694159 Clinical Trial.
Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA. Figura NB, et al. Among authors: sahebjam s. Breast Cancer Res Treat. 2019 Jun;175(3):781-788. doi: 10.1007/s10549-019-05170-7. Epub 2019 Mar 11. Breast Cancer Res Treat. 2019. PMID: 30859348
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.
Tolaney SM, Sahebjam S, Rhun EL, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. Tolaney SM, et al. Among authors: sahebjam s. Clin Cancer Res. 2021 Mar 1;27(5):1582. doi: 10.1158/1078-0432.CCR-21-0193. Clin Cancer Res. 2021. PMID: 33649192 No abstract available.
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P. Lin NU, et al. Among authors: sahebjam s. J Clin Oncol. 2021 Aug 20;39(24):2667-2675. doi: 10.1200/JCO.20.02822. Epub 2021 May 4. J Clin Oncol. 2021. PMID: 33945296 Free PMC article. Clinical Trial.
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw M. Singh K, et al. Among authors: sahebjam s. Clin Cancer Res. 2022 Feb 15;28(4):585-593. doi: 10.1158/1078-0432.CCR-21-2681. Clin Cancer Res. 2022. PMID: 34561270 Free PMC article. Review.
Reply to J. Wei et al.
Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P. Lin NU, et al. Among authors: sahebjam s. J Clin Oncol. 2021 Dec 20;39(36):4127-4128. doi: 10.1200/JCO.21.01973. Epub 2021 Oct 12. J Clin Oncol. 2021. PMID: 34637335 No abstract available.
77 results